Tumor suppressor serine/threonine kinase LKB1 expression, not kinase activity, increased in the vascular smooth muscle cells and neointima in the rat carotid artery injury model

Korean Circulation Journal

Volumn 40, Issue 11, 2010, Pages 552-557

  Jeong, Jin Ok ^a   Kim, Jeong Hee ^b   Ahn, Kye Taek ^a   Park, Hyung Seo ^a   Jang, Won Il ^a   Park, Jae Hyeong ^a   Lee, Jae Hwan ^a   Choi, Si Wan ^a   Kim, Jin Man ^a   Seong, In Whan ^a  

^a Chungnam National University   (South Korea)

^b Eulji University   (South Korea)

Author keywords

Angiotensin II; Coronary restenosis; LKB1 protein, rat

Indexed keywords

ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN II; PROTEIN KINASE LKB1; TUMOR SUPPRESSOR PROTEIN;

ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CAROTID ARTERY INJURY; CELL LYSATE; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME ACTIVITY; IMMUNOHISTOCHEMISTRY; MALE; NEOINTIMA; NONHUMAN; PROTEIN EXPRESSION; RAT; SMOOTH MUSCLE FIBER; VASCULAR SMOOTH MUSCLE; WESTERN BLOTTING;

EID: 78650898669     PISSN: 17385520     EISSN: 17385555     Source Type: Journal    
DOI: 10.4070/kcj.2010.40.11.552     Document Type: Article

References (25)

1. Clowes AW, Reidy MA, Clowes MM. Mechanisms of stenosis after arterial injury. Lab Invest 1983;49:208-15.
2. Dussaillant GR, Mintz GS, Pichard AD, et al. Small stent size and intimal hyperplasia contribute to restenosis: a volumetric intravascular ultrasound analysis. J Am Coll Cardiol 1995;26:720-4.
3. Hoffmann R, Mintz GS, Dussaillant GR, et al. Patterns and mechanisms of in-stent restenosis: a serial intravascular ultrasound study. Circulation 1996;94:1247-54.
4. Schwartz SM, deBlois D, O'Brien ER. The intima: soil for atherosclerosis and restenosis. Circ Res 1995;77:445-65.
5. Hemminki A, Markie D, Tomlinson I, et al. A serine/threonine kinase gene defective in Peutz-Jeghers syndrome. Nature 1998;391:184-7.
6. Jenne DE, Reimann H, Nezu J, et al. Peutz-Jeghers syndrome is caused by mutations in a novel serine threonine kinase. Nat Genet 1998;18: 38-43.
7. Ylikorkala A, Rossi DJ, Korsisaari N, et al. Vascular abnormalities and deregulation of VEGF in Lkb1-deficient mice. Science 2001;293:1323-6.
8. Le vine AJ. p53, the cellular gatekeeper for growth and division. Cell 1997;88:323-31.
9. Sherr CJ. Mammalian G1 cyclins and cell cycle progression. Proc Assoc Am Physicians 1995;107:181-6.
10. Tiainen M, Vaahtomeri K, Ylikorkala A, Makela TP. Growth arrest by the LKB1 tumor suppressor: induction of p21 (WAF1/CIP1). Hum Mol Genet 2002;11:1497-504.
11. Tiainen M, Ylikorkala A, Makela TP. Growth suppression by Lkb1 is mediated by a G(1) cell cycle arrest. Proc Natl Acad Sci U S A 1999;96: 9248-51.
12. Karuman P, Gozani O, Odze RD, et al. The Peutz-Jegher gene product LKB1 is a mediator of p53-dependent cell death. Mol Cell 2001;7: 1307-19.
13. Poon M, Marx SO, Gallo R, Badimon JJ, Taubman MB, Marks AR. Rapamycin inhibits vascular smooth muscle cell migration. J Clin Invest 1996;98:2277-83.
14. Kwon JS, Park NK, Jeong IH, et al. A slight variation in the age of rats commonly used as a carotid artery injury model results in a large difference in neointima formation. Korean Cicr J 2007;37:78-83.
15. Kwon JS, Park SS, Kim YG, et al. Perivascular delivery of paclitaxel with F-127 pluronic gel inhibits neointimal hyperplasia in a rat carotid injury model. Korean Circ J 2005;35:221-7.
16. Joe JH, Lim KS, Jin JY, Kim KS. Effect of udenafil vascular smooth muscle cell proliferation and neointimal hyperplasia in rat carotid artery injury model. Korean Circ J 2008;38:320-4.
17. Clowes AW, Reidy MA, Clowes MM. Kinetics of cellular proliferation after arterial injury: I. smooth muscle growth in the absence of endothelium. Lab Invest 1983;49:327-33.
18. Sharpless NE, Ramsey MR, Balasubramanian P, Castrillon DH, DePinho RA. The differential impact of p16(INK4a) or p19(ARF) deficiency on cell growth and tumorigenesis. Oncogene 2004;23:379-85.
19. Kim DW, Chung HK, Park KC, et al. Tumor suppressor LKB1 inhibits activation of signal transducer and activator of transcription 3 (STAT3) by thyroid oncogenic tyrosine kinase rearranged in transformation (RET)/ papillary thyroid carcinoma (PTC). Mol Endocrinol 2007;21:3039-49.
20. Nagata D, Takeda R, Sata M, et al. AMP-activated protein kinase inhibits angiotensin II-stimulated vascular smooth muscle cell proliferation. Circulation 2004;110:444-51.
21. Kojima K, Motoshima H, Tsutsumi A, et al. Rottlerin activates AMPK possibly through LKB1 in vascular cells and tissues. Biochem Biophys Res Commun 2008;376:434-8.
22. Chan AY, Dyck JR. Activation of AMP-activated protein kinase (AMPK) inhibits protein synthesis: a potential strategy to prevent the development of cardiac hypertrophy. Can J Physiol Pharmacol 2005;83: 24-8.
23. Chan AY, Soltys CL, Young ME, Proud CG, Dyck JR. Activation of AMP-activated protein kinase inhibits protein synthesis associated with hypertrophy in the cardiac myocyte. J Biol Chem 2004;279: 32771-9.
24. Motoshima H, Goldstein BJ, Igata M, Araki E. AMPK and cell proliferation: AMPK as a therapeutic target for atherosclerosis and cancer. J Physiol 2006;574:63-71.
25. Marignani PA, Kanai F, Carpenter CL. LKB1 associates with Brg1 and is necessary for Brg1-induced growth arrest. J Biol Chem 2001;276: 32415-8.